Overview of QMSR Quality Management System Requirements
The QMSR (Quality Management System Regulation) under 21 CFR 820.10 aligns U.S. medical device manufacturers with ISO 13485 while maintaining FDA-specific requirements. This hybrid framework ensures international harmonization while upholding U.S. regulatory oversight.
Key Requirements
QMS Documentation and Compliance
Manufacturers must establish and maintain a QMS per ISO 13485 and applicable FDA regulations, and quality system documentation must include quality procedures, risk management approaches, and software validation records.
Regulatory Alignment and Compliance Mandates
Regulatory alignment and compliance requirements include compliance with 21 CFR 830 for a Unique Device Identification (UDI), Compliance with 21 CFR 821 where traceability is required, complaints meeting Medical Device Reporting (MDR) reporting criteria must follow the requirements of 21 CFR 803, and recalls and advisory notices must comply with 21 CFR 806.
Design and Development Controls
Design and development controls are mandatory for Class II, III, and certain Class I devices. The controls must comply with Clause 7.3 of ISO 13485, including design planning, verification, validation, and change control.
Risk-Based Approach
Organizations must identify, control, and monitor processes based on risk, and risk-based decision-making shall be applied to supplier controls, traceability, and software validation.
Control of Outsourced Processes
Manufacturers retain responsibility for compliance, even when outsourcing. Written quality agreements and proportionate supplier controls are required.
Enforcement and FDA Oversight
Failure to comply results in device adulteration under Section 501(h) of the FD&C Act. The FDA retains enforcement authority, ensuring compliance through inspections and regulatory actions.
Conclusion
The QMSR framework integrates ISO 13485 while reinforcing FDA-specific requirements, providing a globally harmonized yet U.S.-compliant quality management system for medical device manufacturers. This alignment reduces redundancy for companies operating in multiple jurisdictions while ensuring regulatory oversight by the FDA.
